"The wording from the FDA briefing suggests that they will want another trial with a more robust procedure before approving the MSC cells given their strongly risk-adverse opinion on stem cell treatments, and the trial outcomes are not nearly strong enough to suggest overwhelming efficacy that many of us here believed would eventuate."
From what I am reading, they only want to discuss measures for product quality control, not another trial. Where are you seeing the request for another trial?
MSB Trading - Aug 2020 on, page-755
Add MSB (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$1.78 |
Change
0.255(16.7%) |
Mkt cap ! $2.032B | |||
| Open | High | Low | Value | Volume |
| $1.74 | $1.83 | $1.71 | $27.76M | 15.59M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 30000 | $1.78 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $1.79 | 48074 | 4 |
View Market Depth
| Last trade - 16.10pm 14/11/2024 (20 minute delay) ? |
| MSB (ASX) Chart |